JP2024533420A - 腎臓病の治療に用いられる５－（３，４－ジクロロフェニル）－ｎ－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシル）－６－（２，２，２－トリフルオロエトキシ）ニコチンアミドの固形形態 - Google Patents

腎臓病の治療に用いられる５－（３，４－ジクロロフェニル）－ｎ－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシル）－６－（２，２，２－トリフルオロエトキシ）ニコチンアミドの固形形態 Download PDF

Info

Publication number
JP2024533420A
JP2024533420A JP2024515556A JP2024515556A JP2024533420A JP 2024533420 A JP2024533420 A JP 2024533420A JP 2024515556 A JP2024515556 A JP 2024515556A JP 2024515556 A JP2024515556 A JP 2024515556A JP 2024533420 A JP2024533420 A JP 2024533420A
Authority
JP
Japan
Prior art keywords
diffraction pattern
characteristic
degrees
crystalline form
onset
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533420A5 (cg-RX-API-DMAC10.html
Inventor
ホンヤン，フゥー
スーイ，ジャン
シュヴィッター，ウルス
ドット，パスカル
ディオドーネ，ラルフ
ウィッテンバッハ，ニコル
グラスマン，オラフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
River 3 Renal Corp
F Hoffmann La Roche AG
Original Assignee
River 3 Renal Corp
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202111049581.4A external-priority patent/CN115772123A/zh
Application filed by River 3 Renal Corp, F Hoffmann La Roche AG filed Critical River 3 Renal Corp
Publication of JP2024533420A publication Critical patent/JP2024533420A/ja
Publication of JP2024533420A5 publication Critical patent/JP2024533420A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024515556A 2021-09-08 2022-09-08 腎臓病の治療に用いられる５－（３，４－ジクロロフェニル）－ｎ－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシル）－６－（２，２，２－トリフルオロエトキシ）ニコチンアミドの固形形態 Pending JP2024533420A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202111049581.4A CN115772123A (zh) 2021-09-08 2021-09-08 固体形式
CN202111049581.4 2021-09-08
US202163243813P 2021-09-14 2021-09-14
US63/243,813 2021-09-14
PCT/US2022/042905 WO2023039063A1 (en) 2021-09-08 2022-09-08 Solid form of 5-(3,4-dichlorophenyl)-n-((1r,2r)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide for use in treating kidney diseases

Publications (2)

Publication Number Publication Date
JP2024533420A true JP2024533420A (ja) 2024-09-12
JP2024533420A5 JP2024533420A5 (cg-RX-API-DMAC10.html) 2025-09-12

Family

ID=83594511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515556A Pending JP2024533420A (ja) 2021-09-08 2022-09-08 腎臓病の治療に用いられる５－（３，４－ジクロロフェニル）－ｎ－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシル）－６－（２，２，２－トリフルオロエトキシ）ニコチンアミドの固形形態

Country Status (7)

Country Link
US (3) US11814354B2 (cg-RX-API-DMAC10.html)
EP (1) EP4399201A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024533420A (cg-RX-API-DMAC10.html)
AU (1) AU2022342069A1 (cg-RX-API-DMAC10.html)
CA (1) CA3231117A1 (cg-RX-API-DMAC10.html)
TW (1) TW202334088A (cg-RX-API-DMAC10.html)
WO (1) WO2023039063A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11814354B2 (en) 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504534A (ja) * 2009-09-11 2013-02-07 エフ．ホフマン−ラ ロシュ アーゲー Ｈｄｌコレステロール上昇剤としての５−（３，４−ジクロロ−フェニル）−ｎ−（２−ヒドロキシ−シクロヘキシル）−６−（２，２，２−トリフルオロ−エトキシ）−ニコチンアミド及びその塩
WO2020021097A1 (en) * 2018-07-26 2020-01-30 F. Hoffmann-La Roche Ag Compounds for use in treating kidney disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US20120101282A1 (en) 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
WO2014180741A1 (en) 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US11814354B2 (en) 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504534A (ja) * 2009-09-11 2013-02-07 エフ．ホフマン−ラ ロシュ アーゲー Ｈｄｌコレステロール上昇剤としての５−（３，４−ジクロロ−フェニル）−ｎ−（２−ヒドロキシ−シクロヘキシル）−６−（２，２，２−トリフルオロ−エトキシ）−ニコチンアミド及びその塩
WO2020021097A1 (en) * 2018-07-26 2020-01-30 F. Hoffmann-La Roche Ag Compounds for use in treating kidney disorders

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Ｃ．Ｇ．ＷＥＲＭＵＴＨ編, 最新 創薬化学 下巻, JPN6014029314, 1999, pages 347 - 365, ISSN: 0005886070 *
CAIRA, M.R.: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, JPN6014016881, 1998, pages 163 - 208, ISSN: 0005886067 *
化学実験操作法 上巻, JPN6010029432, 1963, pages 371 - 399, ISSN: 0005886068 *
医薬品の残留溶媒ガイドラインについて, JPN6023047248, 1998, ISSN: 0005886071 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014022315, 2008, pages 10 - 11, ISSN: 0005886066 *
橋田 充, 経口投与製剤の設計と評価, JPN6008031302, 10 February 1995 (1995-02-10), pages 76 - 79, ISSN: 0005886069 *

Also Published As

Publication number Publication date
US20250263378A1 (en) 2025-08-21
CA3231117A1 (en) 2023-03-16
US11814354B2 (en) 2023-11-14
US12134599B2 (en) 2024-11-05
WO2023039063A1 (en) 2023-03-16
US20240300895A1 (en) 2024-09-12
US20230242485A1 (en) 2023-08-03
TW202334088A (zh) 2023-09-01
EP4399201A1 (en) 2024-07-17
AU2022342069A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
JP7797575B2 (ja) ７ｈ－ピロロ［２，３－ｄ］ピリミジンｊａｋ－阻害剤
AU2018373122A1 (en) Crystalline forms of N-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
KR20170125893A (ko) 니코틴아미드 리보사이드의 결정 형태
JP2022502500A (ja) 補体因子ｄ阻害剤の形態
KR20220019772A (ko) 2,4,6-트리플루오로-n-[6-(1-메틸-피페리딘-4-카르보닐)-피리딘-2-일]-벤즈아미드 헤미숙시네이트의 대규모 제조를 위한 방법 및 중간체, 및 2,4,6-트리플루오로-n-[6-(1-메틸-피페리딘-4-카르보닐)-피리딘-2-일]-벤즈아미드 아세테이트의 제조
CN105189513A (zh) 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态
JP2014144916A (ja) ２−アシルアミノチアゾール化合物の結晶
CA3031343C (en) Salts of 2,6-Dimethylpyrimidone derivatives and their uses
US20250263378A1 (en) Solid forms
WO2026008074A1 (zh) 补体因子b抑制剂的晶型、其制备方法及用途
US20240199645A1 (en) Polymorphic forms of (s)-12-fluoro-4-(1-methyl-1h-pyrazol-5-yl)-7a,8,13,14-tetrahydro-7h-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine
US20240368185A1 (en) Macrocyclic azolopyridines
CN102190656B (zh) 含有五元杂环的噁唑烷酮抗菌素
CN115772123A (zh) 固体形式
CA2934456C (en) Fused heterocyclic compounds as ion channel modulators
WO2018024236A1 (zh) 一种jak1选择性抑制剂的新晶型及其制备方法和用途
US20250243242A1 (en) Levodopa tyrosine polymorphs
WO2025101874A1 (en) Crystalline salt forms of the tyrosine kinase inhibitor ecf506
HK1225728A1 (en) Fused heterocyclic compounds as ion channel modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260616